SIGLEC1 and COVID-19: The normalization employed in the original publication, DSB, did not accurately represent these trends, masking positive expression of CD169 (Supplementary Fig. 20), failing to identify upregulation of CD169 with COVID-19 in any monocyte subset, and reducing signal of CD38 and CD64 in CD16 monocytes (Supplementary Fig. 19C).